Top

Clinical Rheumatology

Published in:

01-10-2020 | Osteoarthrosis | Original Article

Profile of common inflammatory markers in treatment-naïve patients with systemic rheumatic diseases

Authors: Min Jung Kim, Eun Bong Lee, Yeong Wook Song, Jin Kyun Park

Published in: Clinical Rheumatology | Issue 10/2020

Abstract

Objectives

To evaluate and compare the clinical implications of common inflammatory markers in systemic rheumatic diseases (SRDs).

Method

We investigated the profiles of erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and white blood cell (WBC) count in treatment-naïve patients with SRDs, osteoarthritis and pneumonia diagnosed at Seoul National University Hospital during 2004–2016. SRDs included rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), ankylosing spondylitis (AS), systemic sclerosis (SSc), idiopathic inflammatory myopathy (IIM) and adult-onset Still’s disease (AOSD). Associations between inflammatory markers were evaluated using Pearson’s correlation and regression analysis. ROC curve analysis was performed to examine the predictive value of inflammatory markers for SRD diagnosis.

Results

We identified a total of 1191 patients. Leukocytosis was present in < 20% SRD patients. There was marked variability in ESR and CRP levels among different SRDs. The highest mean CRP levels (mean ± SD, mg/dL) were observed in AOSD (11.3 ± 7.9), followed by RA (2.0 ± 3.3), IIM (1.8 ± 3.5), SLE (1.5 ± 3.1), SSc (0.6 ± 1.3) and AS (0.08 ± 0.1). Mean ESR (mm/h) was also highest in AOSD (71.2 ± 31.0), followed by SLE (47.3 ± 34.2), RA (45.5 ± 30.6), IIM (40.8 ± 24.8) and SSc (27.8 ± 26.0). All SRDs showed significant positive correlations between ESR and CRP: greatest in RA (r = 0.53, p < 0.001) and weakest in SLE (r = 0.20, p = 0.03). WBC correlated weakly with CRP but not with ESR in most SRDs. While the AUC for WBC count was less than that of ESR or CRP, the AUC for ESR and CRP were similar in SRD. The optimal cuff-off values for inflammatory markers predicting SRD were within or slightly above the normal limit.

Conclusions

ESR, CRP and WBC are not always elevated in treatment-naïve patients with SRD. Individual SRDs have a unique profile of inflammatory markers. However, routine inflammatory markers should still be interpreted with caution when diagnosing and assessing disease activity in those with SRD.

Key Points

•Leukocytosis and elevation of ESR and CRP are not always present in all systemic rheumatic diseases.

•Inflammatory markers are often dissociated and they are not specific for disease diagnosis.

•Better biomarkers, which measure disease-specific local and systemic inflammation, are needed.

Available only for authorised users

Zweifach BW, Grant L, McCluskey RT (2014) The inflammatory process. Academic Press, New York

Gruys E, Toussaint M, Niewold T, Koopmans S (2005) Acute phase reaction and acute phase proteins. J Zhejiang Univ Sci B 6:1045–1056CrossRef

Heinrich PC, Castell JV, Andus T (1990) Interleukin-6 and the acute phase response. Biochem J 265:621–636CrossRef

Feldman M, Aziz B, Kang GN, Opondo MA, Belz RK, Sellers C (2013) C-reactive protein and erythrocyte sedimentation rate discordance: frequency and causes in adults. Transl Res 161:37–43CrossRef

Keenan R, Swearingen C, Yazici Y (2008) Erythrocyte sedimentation rate and C-reactive protein levels are poorly correlated with clinical measures of disease activity in rheumatoid arthritis, systemic lupus erythematosus and osteoarthritis patients. Clin Exp Rheumatol 26:814–819PubMed

Syed KM, Pinals RS (1996) Leukocytosis in rheumatoid arthritis. J Clin Rheumatol 2:197–202CrossRef

Go DJ, Lee EY, Lee EB, Song YW, Konig MF, Park JK (2016) Elevated erythrocyte sedimentation rate is predictive of interstitial lung disease and mortality in dermatomyositis: a Korean retrospective cohort study. J Korean Med Sci 31:389–396. https://doi.org/10.3346/jkms.2016.31.3.389CrossRefPubMedPubMedCentral

Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, Healey LA, Kaplan SR, Liang MH, Luthra HS et al (1988) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:315–324CrossRef

Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581CrossRef

10.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725–1725CrossRef

11.

Linden SVD, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum 27:361–368CrossRef

12.

Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA, Carreira PE (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Arthritis Rheum 65:2737–2747CrossRef

13.

Yamaguchi M, Ohta A, Tsunematsu T, Kasukawa R, Mizushima Y, Kashiwagi H, Kashiwazaki S, Tanimoto K, Matsumoto Y, Ota T (1992) Preliminary criteria for classification of adult Still’s disease. J Rheumatol 19:424–430PubMed

14.

Bohan A, Peter JB (1975) Polymyositis and dermatomyositis. N Engl J Med 292:344–347CrossRef

15.

Siemons L, ten Klooster PM, Vonkeman HE, van Riel PL, Glas CA, van de Laar MA (2014) How age and sex affect the erythrocyte sedimentation rate and C-reactive protein in early rheumatoid arthritis. BMC Musculoskelet Disord 15:368CrossRef

16.

Lakoski SG, Cushman M, Criqui M, Rundek T, Blumenthal RS, D'Agostino RB Jr, Herrington DM (2006) Gender and C-reactive protein: data from the Multiethnic Study of Atherosclerosis (MESA) cohort. Am Heart J 152:593–598CrossRef

17.

Ranganath VK, Elashoff DA, Khanna D, Park G, Peter JB, Paulus HE (2005) Age adjustment corrects for apparent differences in erythrocyte sedimentation rate and C-reactive protein values at the onset of seropositive rheumatoid arthritis in younger and older patients. J Rheumatol 32:1040–1042PubMed

18.

Isaacs A, Lindenmann J (1957) Virus interference. I. The interferon. Pro R Soc Lond B Biol Sci 147:258–267CrossRef

19.

Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67:227–264CrossRef

20.

Dinarello CA (2000) Proinflammatory cytokines. Chest 118:503–508CrossRef

21.

Pinsky MR, Vincent J-L, Deviere J, Alegre M, Kahn RJ, Dupont E (1993) Serum cytokine levels in human septic shock: relation to multiple-system organ failure and mortality. Chest 103:565–575CrossRef

22.

Holub M, Lawrence DA, Andersen N, Davidová A, Beran O, Marešová V, Chalupa P (2013) Cytokines and chemokines as biomarkers of community-acquired bacterial infection. Mediat Inflamm 2013:190145. https://doi.org/10.1155/2013/190145CrossRef

23.

McNab F, Mayer-Barber K, Sher A, Wack A, O'Garra A (2015) Type I interferons in infectious disease. Nat Rev Immunol 15:87–103. https://doi.org/10.1038/nri3787CrossRefPubMedPubMedCentral

24.

O'Shea JJ, Ma A, Lipsky P (2002) Cytokines and autoimmunity. Nat Rev Immunol 2:37CrossRef

25.

Maria AT, Le Quellec A, Jorgensen C, Touitou I, Riviere S, Guilpain P (2014) Adult onset Still’s disease (AOSD) in the era of biologic therapies: dichotomous view for cytokine and clinical expressions. Autoimmun Rev 13:1149–1159. https://doi.org/10.1016/j.autrev.2014.08.032CrossRefPubMed

26.

Schett G, Elewaut D, McInnes IB, Dayer J-M, Neurath MF (2013) How cytokine networks fuel inflammation: toward a cytokine-based disease taxonomy. Nat Med 19:822–824CrossRef

27.

Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc J-L (2014) Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case/non-case study in a nationwide pharmacovigilance database. Rheumatology 53:1864–1871. https://doi.org/10.1093/rheumatology/keu214CrossRefPubMed

28.

Gaitonde S, Samols D, Kushner I (2008) C-reactive protein and systemic lupus erythematosus. Arthritis Care Res (Hoboken) 59:1814–1820CrossRef

29.

Honig S, Gorevic P, Weissmann G (1977) C-reactive protein in systemic lupus erythematosus. Arthritis Rheum 20:1065–1070CrossRef

30.

Becker G, Waldburger M, Hughes G, Pepys M (1980) Value of serum C-reactive protein measurement in the investigation of fever in systemic lupus erythematosus. Ann Rheum Dis 39:50–52CrossRef

31.

Hill AS (1951) C-reactive protein in the chronic rheumatic diseases. Lancet 2:807–811CrossRef

32.

Aringer M (2019) Inflammatory markers in systemic lupus erythematosus. J Autoimmun. https://doi.org/10.1016/j.jaut.2019.102374

33.

Greenberg SA (2010) Type 1 interferons and myositis. Arthritis Res Ther 12:1–7. https://doi.org/10.1186/ar2885CrossRef

34.

Greenberg SA (2010) Dermatomyositis and type 1 interferons. Curr Rheumatol Rep 12:198–203. https://doi.org/10.1007/s11926-010-0101-6CrossRefPubMedPubMedCentral

35.

Salajegheh M, Kong SW, Pinkus JL, Walsh RJ, Liao A, Nazareno R, Amato AA, Krastins B, Morehouse C, Higgs BW, Jallal B, Yao Y, Sarracino DA, Parker KC, Greenberg SA (2010) Interferon-stimulated gene 15 (ISG15) conjugates proteins in dermatomyositis muscle with perifascicular atrophy. Ann Neurol 67:53–63. https://doi.org/10.1002/ana.21805CrossRefPubMedPubMedCentral

36.

Park JK, Gelber AC, George M, Danoff SK, Qubti MA, Christopher-Stine L (2013) Pulmonary impairment, not muscle injury, is associated with elevated ESR in the idiopathic inflammatory myopathies. Rheumatology (Oxford) 52:1336–1338. https://doi.org/10.1093/rheumatology/ket162CrossRef

37.

Gupta P, Friberg LE, Karlsson MO, Krishnaswami S, French J (2010) A semi-mechanistic model of CP-690,550-induced reduction in neutrophil counts in patients with rheumatoid arthritis. J Clin Pharmacol 50:679–687CrossRef

38.

Tanaka Y, McInnes IB, Taylor PC, Byers NL, Chen L, de Bono S, Issa M, Macias WL, Rogai V, Rooney TP (2018) Characterization and changes of lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis: an integrated analysis. Arthritis Rheum 70:1923–1932CrossRef

39.

Smith E, Jorgensen A, Beresford M (2017) Do classic blood biomarkers of JSLE identify active lupus nephritis? Evidence from the UK JSLE cohort study. Lupus 26:1212–1217CrossRef

40.

Schäfer VS, Weiß K, Krause A, Schmidt WA (2018) Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity. Clin Rheumatol 37:1835–1844CrossRef

41.

Gabay C, Fautrel B, Rech J, Spertini F, Feist E, Kötter I, Hachulla E, Morel J, Schaeverbeke T, Hamidou MA (2018) Open-label, multicentre, dose-escalating phase II clinical trial on the safety and efficacy of tadekinig alfa (IL-18BP) in adult-onset Still’s disease. Ann Rheum Dis 77:840–847PubMedPubMedCentral

42.

Muangchan C, Harding S, Khimdas S, Bonner A, Group CSR, Baron M, Pope J (2012) Association of C-reactive protein with high disease activity in systemic sclerosis: results from the Canadian Scleroderma Research Group. Arthritis Care Res (Hoboken) 64:1405–1414CrossRef

43.

Yayla ME, İlgen U, Okatan İE, UsluYurteri E, Torgutalp M, Dinçer ABK, Gülöksüz EGA, Sezer S, Turgay TM, Kınıklı G (2020) Association of simple hematological parameters with disease manifestations, activity, and severity in patients with systemic sclerosis. Clin Rheumatol 39:77–8

Title: Profile of common inflammatory markers in treatment-naïve patients with systemic rheumatic diseases
Authors: Min Jung Kim
Eun Bong Lee
Yeong Wook Song
Jin Kyun Park
Publication date: 01-10-2020
Publisher: Springer International Publishing
Keywords: Osteoarthrosis
Systemic Lupus Erythematosus
Polymyositis
Systemic Sclerosis
Polymyositis
Osteoarthrosis
Pneumonia
Ankylosing Spondylitis
Rheumatoid Arthritis
Dermatomyositis
Leukocytosis
Cytokines
Published in: Clinical Rheumatology / Issue 10/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI: https://doi.org/10.1007/s10067-020-05049-9

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Objectives

Method

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 10/2020

Correction to: The IgG galactosylation ratio is higher in spondyloarthritis patients and associated with the MRI score

Elevated CRP even at the first visit to a rheumatologist is associated with long-term poor outcomes in patients with psoriatic arthritis

Is it time to say goodbye to weekly rituximab in ANCA vasculitis?

Giant cell arteritis with normal inflammatory markers: case report and review of the literature

A 9-year-old girl with Kawasaki disease and pulmonary nodules

Cerebrospinal fluid levels of BAFF and APRIL as direct indicators of disease activity in anti-neutrophil cytoplasmic antibody–related hypertrophic pachymeningitis

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials